News Digest / Ticker: MNPR

Ticker: MNPR

09:14am, Tuesday, Aug 12, 2025

Monopar advances ALXN1840 NDA, MNPR-101 trials with cash runway into late 2026

Snapshot - Monopar Therapeutics Inc (NASDAQ: MNPR) Clinical-stage biopharma advancing ALXN1840 (Wilson disease) and MNPR‑101 radiopharmaceuticals; filing an NDA planned for early 2026 and continuing Phase 1 radiopharma trials while managing cash runway into late 2026. Key facts & figures (straigh...

09:07am, Tuesday, May 13, 2025

Monopar Therapeutics Reports Increased Q1 Losses Amid Rising Operating Expenses and R&D Costs